Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$39.95 USD
-0.20 (-0.50%)
Updated Dec 8, 2023 04:00 PM ET
After-Market: $39.93 -0.02 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Earnings News For HALO
-
Why Is Halozyme Therapeutics (HALO) Up 2.8% Since Last Earnings Report?
-
Halozyme (HALO) Q3 Earnings Top Estimates, Revenues Lag
-
Halozyme Therapeutics: Q3 Earnings Snapshot
-
Halozyme Therapeutics (HALO) Q3 Earnings Surpass Estimates
-
HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
-
Halozyme Therapeutics (HALO) Down 3.8% Since Last Earnings Report: Can It Rebound?
-
Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised
-
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Top Estimates
-
Halozyme Therapeutics: Q2 Earnings Snapshot
-
HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
-
Halozyme Therapeutics (HALO) Up 0.7% Since Last Earnings Report: Can It Continue?
-
Halozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y
-
Halozyme Therapeutics (HALO) Q1 Earnings and Revenues Miss Estimates
-
Halozyme Therapeutics: Q1 Earnings Snapshot
-
HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS
-
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
-
Halozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound?
-
Halozyme (HALO) Q4 Earnings Top, Revenues Miss, Stock Down
-
Halozyme Therapeutics (HALO) Q4 Earnings Surpass Estimates
-
Halozyme Therapeutics: Q4 Earnings Snapshot
-
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS
-
Halozyme Therapeutics (HALO) Up 16.2% Since Last Earnings Report: Can It Continue?
-
Halozyme's (HALO) Q3 Earnings and Revenues Surpass Estimates
-
Halozyme Therapeutics (HALO) Surpasses Q3 Earnings and Revenue Estimates
-
Halozyme Therapeutics: Q3 Earnings Snapshot